FDA Warning/Regulatory Alert Note from the OQSV Evidence-Based Practice: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released since completion of the CPG.
Recommendation Against Continued Use:October 8, 2010 – Sibutramine Hydrocloride: On October 8, 2010, the U.S. Food and Drug Administration (FDA) asked Abbott Laboratories to voluntarily withdraw from the U.S. market, its weight loss drug Meridia (sibutramine) because of clinical trial data indicating an increased risk of cardiovascular adverse events, including heart attack and stroke, in the studied population. Abbott has agreed to voluntarily stop marketing of Meridia in the United States.
About the CPG
The guideline is formatted as two algorithms, with annotations:
- Screening for OBE
- Treatment for weight loss and weight management
The guideline describes the critical decision points in the Management of Obesity and Overweight and provides clear and comprehensive evidence based recommendations incorporating current information and practices for practitioners throughout the DoD and VA Health Care systems. The guideline is intended to improve patient outcomes and local management of patients who are obese or overweight.
Disclaimer: This Clinical Practice Guideline is intended for use only as a tool to assist a clinician/healthcare professional and should not be used to replace clinical judgment.